Please login to the form below
paclitaxel
This page shows the latest paclitaxel news and features for those working in and with pharma, biotech and healthcare.
Celgene’s Abraxane fails pancreatic cancer trial
Abraxane (nab-paclitaxel) is already approved to treat patients with advanced metastatic pancreatic cancer, but Celgene had been hoping to get approval for the drug as an adjuvant therapy given after
Latest news
-
Tecentriq gains first IO approval in triple negative breast cancer
Tecentriq (atezolizumab) can now be used in combination with chemotherapy (Celgene’s Abraxane, nab-paclitaxel) in adults with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) and whose tumours ... The company says safety
-
Pfizer closes on EU approval of lung cancer drug Vizimpro
paclitaxel or nab-paclitaxel chemotherapy, while Roche’s rival Tecentriq (atezolizumab) was recommended for adults with locally-advanced or metastatic bladder cancer , specifically after prior platinum-containing chemotherapy, or in patients
-
Ocrevus helps Roche shrug off biosimilars in 2018
It made 248 francs in the fourth quarter, indicating that it could be in blockbuster territory in 2019, helped by a new FDA approval in combination with Avastin, paclitaxel and carboplatin
-
Chi-Med and Lilly’s cancer drug Elunate a milestone for China
Chi-Med has a pivotal phase 3 trial of fruquintinib as a second line combination with paclitaxel in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma due in the first
-
AZ drug matched to cancer mutation passes phase 2 test
At this year’s ASCO meeting, the results of the phase 2 PAKT trial in triple negative breast cancer (TNBC) showed that adding the drug to first-line therapy with paclitaxel ... resulted in significant extensions in both progression-free survival (to
More from news
Approximately 9 fully matching, plus 105 partially matching documents found.
Latest Intelligence
-
Immuno-oncology in 2019: the rapid evolution continues
An FDA ruling on Tecentriq in combination with carboplatin and nab-paclitaxel (Abraxane) as a first-line treatment for patients with metastatic non-squamous NSCLC (based on the IMpower130 trial) is
-
Pharma deals in May 2015
Sorrento (Igdrasol)/ NantPharma. Asset acquisition. Acquisition of Igdrasol including Cynviloq (paclitaxel nanoparticle).
-
The rise of chronic disease in BRIC markets
For late-stage patients, Brazil physicians are more likely to use an anthracycline-based regimen without a taxane in the first line, gemcitabine, paclitaxel or a combination of both in the
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
BMS appoints oncology development head
Dr Namouni first joined Bristol-Myers Squibb in France in 1999 as a life-cycle manager for chemotherapy drug Taxol (paclitaxel) and has since held a number of increasingly senior positions
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Experienced / Senior Account Director - Publications - London
-
Up to £80, 000 plus great benefits
-
Director – Healthcare PR
-
Salary TBC
- Project Manager - Digital Healthcare - London
-
Excellent Remuneration Package
- Project Manager - Medical Communications – South Wales
-
Excellent Remuneration Package
-
Senior Medical Writer
-
Salary TBC
- Senior Account Director/ Associate Director- Pharma and Life Sci...
-
Competitive salary and benefits
- Freelance Medical Writer - Healthcare Advertising - London
-
Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day
- Senior Account Manager- Pharma and Life Scienes
-
Competitive salary and benefits
- Editor – Medical Education Agency – Bucks
-
Salary TBC
- Account Manager / Senior Account Manager - Healthcare Advertisin...
-
Excellent Remuneration
-
Account Director, Medical Education
-
Salary TBC
-
Senior Medical Writer
-
Competitive salary and benefits
- Account Director – London based Medical Communications Agency
-
Excellent Remuneration Package
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
- Senior / Principal Medical Writer - MedComms - Home Based / Vari...
-
Excellent Remuneration Packages
Subscribe to our email news alerts
- With Spiriva under pressure, Boehringer moves to bolster pipeline
- Genfit claims FDA breakthrough status for liver disease drug
- Mereo’s shareholders back OncoMed takeover
- Lucid Group announces the appointment of new CFO
- From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
- Q&A: Niels Lund
PMHub
Wisepress
Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...
Latest intelligence
- From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
- How pharma is progressing their commitment in patient engagement...
- Cuttsy+Cuttsy awarded CPD Platinum by the IPA
- Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
- Breaking Bad
- Six behaviours separate the good brand teams from the bad...
Quick links
Infographics
